Ceregene

Ceregene, Inc. is a private biotechnology company based in San Diego that focuses on the treatment of major neurodegenerative diseases using neurotrophic factors. The company's clinical programs include CERE-110, an AAV2-based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer's disease.